Global Lysosomal Storage Disease (LSD) Market (Fabry, Gaucher & Pompe): Industry Analysis & Outlook (2018-2022)
Lysosomal Storage Disease (LSD) is a genetic disorder that causes various types of nervous system disorders such as clinical abnormalities and cellular dysfunction. There are more than 65 categories of LSD. This disease can be classified into Lipid Metabolism Disorder and Glycoprotein Metabolism Disorder. Further Lipid Metabolism Disorder is categorized into Gaucher disease & Fabry disease and Glycoprotein Metabolism Disorder into Pompe disease. LSD develops mainly due to deficiency of lysosomal enzyme in the living body. A person suffering from LSD could experience problems like abnormal growth of bones, delay movement of body, deafness, blindness, dementia, respiratory problems, fatigue/weakness, bone & joint deformity, organ enlargement, lung dysfunction, severe & fatal physical & mental health deterioration.
The global LSD market is expected to grow with growing Ashkenazi (Eastern and Western Europe) population, increasing pharmaceutical R&D spending, growing disposable income, rising healthcare expenditure and accelerating economic growth. Key trends of this rare disease market includes progressing drugs under pipeline and increasing preference towards gene therapy. However, there are some factors which can hinder growth of the market including stringent regulations and limited access to patent rights.
The report “Global Lysosomal Storage Disease (LSD) Market (Fabry, Gaucher & Pompe): Industry Analysis & Outlook (2018-2022)” by Koncept Analytics provides an extensive research and detailed analysis of the present market along with future outlook.
The report discusses the major growth drivers, key tends & developments and challenges of the market, covering the global market. The report profiles the key players of the market including Pfizer Inc., Sanofi S.A., Shire Plc and Protalix BioTherapeutics, Inc.
- 1. Market Overview
- 1.1 Lysosomal Storage Disease (LSD)
- 1.2 Classification of LSD
- Table 1: Classification of Lysosomal Storage Disease (LSD)
- Table 2: Categories of Gaucher Disease by Clinical Types
- 1.3 Symptoms
- 1.4 Diagnosis
- 1.5 Treatment
- 1.6 Upcoming Treatment
- 2. Global LSD Market Analysis
- 2.1 Global LSD Market Forecast by Value
- Table 3: Global LSD Market Forecast by Value (2017-2022)
- 2.2 Global LSD Market Value by Category
- Table 4: Global LSD Market Value by Category (2017)
- 2.3 Global Fabry Disease Market Forecast by Value
- Table 5: Global Fabry Disease Market Forecast by Value (2017-2022)
- 2.4 Global Fabry Disease Market Value by Drugs
- Table 6: Global Fabry Disease Market Value by Drugs (2017)
- 2.4.1 Global Fabrazyme Sales Value
- Table 7: Global Fabrazyme Sales Value (2017-2022)
- 2.4.2 Global Replagal Sales Value
- Table 8: Global Replagal Sales Value (2017-2022)
- 2.4.3 Global Galafold Sales Value
- Table 9: Global Galafold Sales Value (2017-2022)
- 2.5 Global Gaucher Disease Market Forecast by Value
- Table 10: Global Gaucher Disease Market Forecast by Value (2017-2022)
- 2.6 Global Gaucher Disease Market Value by Drugs
- Table 11: Global Gaucher Disease Market Value by Drugs (2017)
- 2.6.1 Global Cerezyme Sales Value
- Table 12: Global Cerezyme Sales Value (2017-2022)
- 2.6.2 Global Vipriv Sales Value
- Table 13: Global Vipriv Sales Value (2017-2022)
- 2.6.3 Global Cerdelga Sales Value
- Table 14: Global Cerdelga Sales Value (2017-2022)
- 2.7 Global Pompe Disease Market Forecast by Value
- Table 15: Global Pompe Disease Market Forecast by Value (2017-2022)
- 2.8 Global Pompe Disease Market Value by Drugs
- 2.8.1 Global Myozyme Sales Value
- Table 16: Global Myozyme Sales Value (2017-2022)
- 3. Market Dynamics
- 3.1 Growth Drivers
- 3.1.1 Growing Ashkenazi (Eastern and Western Europe) Population
- Table 17: Ashkenazi (Eastern and Western Europe) Population (2013-2017)
- 3.1.2 Rising Pharmaceutical R&D Spending
- Table 18: Global Pharmaceutical R&D Spending (2013-2017)
- 3.1.3 Increasing Disposable Income
- Table 19: Global Gross National Income (GNI) Per Capita (2013-2017)
- 3.1.4 Growing Healthcare Expenditure
- Table 20: Global Healthcare Expenditure (2013-2017)
- 3.1.5 Accelerating Economic Growth
- Table 21: Global GDP Per Capita (2013-2017)
- 3.2 Key Trends & Developments
- 3.2.1 Progressing Drugs under Pipeline
- Table 22: Drugs under Development for Lysosomal Storage Disease (2017)
- 3.2.2 Increasing Preference towards Gene Therapy
- 3.3 Challenges
- 3.3.1 Stringent Regulations
- 3.3.2 Limited Access to Patent Rights
- 4. Competitive Landscape
- 4.1 Global Market
- 4.1.1 Revenue Comparison of Key Players
- Table 23: Global LSD Market Key Players - Revenue Comparison (2017)
- 4.1.2 Market Cap Comparison of Key Players
- Table 24: Global LSD Market Key Players - Market Cap Comparison 4.1.3 Global LSD Market-Annual Treatment Cost Comparison by Company Table 25: Global LSD Market-Annual Treatment Cost Comparison by Company (2017)
- 5. Company Profiles
- 5.1 Pfizer Inc.
- 5.1.1 Business Overview
- Table 26: Pfizer Inc. Revenues by Business Segments (2017)
- 5.1.2 Financial Overview
- Table 27: Pfizer Inc. Revenues and Net Income (2013-2017)
- 5.1.3 Business Strategies
- Table 28: Pfizer Inc. Significant Agreements (2017/2018)
- Table 29: Pfizer Inc. Research and Development Expenditures (2015-2017)
- 5.2 Sanofi S.A.
- 5.2.1 Business Overview
- Table 30: Sanofi S.A. Net Sales by Business Segments (2017)
- 5.2.2 Financial Overview
- Table 31: Sanofi S.A. Net Sales and Net Income (2013-2017)
- 5.2.3 Business Strategies
- Table 32: Sanofi S.A. Significant Acquisitions (2017/2018)
- Table 33: Sanofi S.A. Research and Development Expenditure (2015-2017)
- 5.3 Shire Plc
- 5.3.1 Business Overview
- Table 34: Shire Plc. Revenues by Therapeutic Areas (2017)
- 5.3.2 Financial Overview
- Table 35: Shire Plc Revenues and Net Income (2013-2017)
- 5.3.3 Business Strategies
- Table 36: Shire Plc Research and Development Expenditures (2015-2017)
- Table 37: Shire Plc Advertising and Promotion Expenditure (2015-2017)
- 5.4 Protalix BioTherapeutics, Inc.
- 5.4.1 Business Overview
- Table 38: Protalix BioTherapeutics, Inc. Product Pipeline (2017)
- 5.4.2 Financial Overview
- Table 39: Protalix BioTherapeutics, Inc. Revenues and Net Income (Loss) (2013-2017) 5.4.3 Business Strategies
- Table 40: Protalix BioTherapeutics, Inc. Research and Development Expenditures (2015-2017)
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook